Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-Abl. Here, NFKB1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.